SEC Form 10-Q filed by Tarsus Pharmaceuticals Inc.
$TARS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $75.00 | Outperform | Oppenheimer |
| 5/27/2025 | $72.00 | Buy | H.C. Wainwright |
| 11/20/2023 | $19.00 | Neutral | Goldman |
| 7/18/2023 | $44.00 | Outperform | William Blair |
| 5/18/2023 | Buy | Guggenheim | |
| 8/1/2022 | $40.00 | Overweight | Barclays |
| 12/21/2021 | $40.00 | Buy | HC Wainwright & Co. |
| 11/23/2021 | $55.00 | Outperform | Oppenheimer |
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 11th, at 11:30 a.m. PT / 2:30 p.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advanci
Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial momentum Management to host conference call today, November 4, 2025, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the third quarter ended September 30, 2025. "Our third quarter results, highlighted by nearly $119 million in XDEMVY sales, reflect the strength of our commercial model, the scale of engagement across eye care, and the impact we're having on patie
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to
Oppenheimer resumed coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $75.00
H.C. Wainwright resumed coverage of Tarsus Pharmaceuticals with a rating of Buy and set a new price target of $72.00
Goldman initiated coverage of Tarsus Pharmaceuticals with a rating of Neutral and set a new price target of $19.00
10-Q - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access
IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. In this new role, she will be responsible for leading the strategy, direction and execution of the Company's new Medical Organization compris
IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests. Mr. Farrow is a seasoned finance and corporate strategy executive with more than two decades of experience successfully leading teams in the life science industry, including several publicly tra
SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial momentum Management to host conference call today, November 4, 2025, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the third quarter ended September 30, 2025. "Our third quarter results, highlighted by nearly $119 million in XDEMVY sales, reflect the strength of our commercial model, the scale of engagement across eye care, and the impact we're having on patie
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and led to a meaningful increase in prescriptions Pipeline advancements and global efforts remain on track Management to host conference call today, August 6, 2025, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the second quarter ended June 30, 2025. "As we approach the two-year anniversary of the XDEMVY launch, we have delivered our stronges